Home/Filings/4/0001209191-15-040710
4//SEC Filing

Horizon Pharma plc 4

Accession 0001209191-15-040710

CIK 0001492426operating

Filed

May 7, 8:00 PM ET

Accepted

May 8, 6:09 PM ET

Size

9.5 KB

Accession

0001209191-15-040710

Insider Transaction Report

Form 4
Period: 2015-05-06
Kelly David George
EVP & Corporate Secretary
Transactions
  • Award

    Performance Share Units (PSU)

    2015-05-06+558,000558,000 total
    Ordinary Shares (558,000 underlying)
Footnotes (2)
  • [F1]Each PSU represents a contingent right to receive ordinary shares of the Issuer, based on the Issuer's level of total shareholder return, as measured from March 23, 2015 through December 22, 2017, March 22, 2018 and June 22, 2018 or based on the level of total shareholder return through any earlier change in control. For such purposes, total shareholder return means the percentage change in the price of the Issuer's ordinary shares on a compounded annual basis, plus the value of reinvested dividends. The number of shares issued may range from zero (0) shares to the maximum number of shares reported in columns 7 and 9 of this report.
  • [F2]The PSU's were approved by the Issuer's Compensation Committee on March 23, 2015, subject to shareholder approval of certain amendments to the Issuer's 2014 Equity Incentive Plan (the "Plan") under which the PSU's were granted. The Issuer's shareholders approved the amendments to the Plan on May 6, 2015.

Issuer

Horizon Pharma plc

CIK 0001492426

Entity typeoperating
IncorporatedIreland

Related Parties

1
  • filerCIK 0001492426

Filing Metadata

Form type
4
Filed
May 7, 8:00 PM ET
Accepted
May 8, 6:09 PM ET
Size
9.5 KB